Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
SRPT

SRPT - Sarepta Therapeutics Inc Stock Price, Fair Value and News

117.52USD+0.69 (+0.59%)Delayed

Market Summary

SRPT
USD117.52+0.69
Delayed
0.59%

SRPT Alerts

  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

SRPT Stock Price

View Fullscreen

SRPT RSI Chart

SRPT Valuation

Market Cap

11.1B

Price/Earnings (Trailing)

657.42

Price/Sales (Trailing)

7.92

EV/EBITDA

116.12

Price/Free Cashflow

-17.56

SRPT Price/Sales (Trailing)

SRPT Profitability

EBT Margin

2.43%

Return on Equity

1.76%

Return on Assets

0.52%

Free Cashflow Yield

-5.7%

SRPT Fundamentals

SRPT Revenue

Revenue (TTM)

1.4B

Rev. Growth (Yr)

63.1%

Rev. Growth (Qtr)

4.2%

SRPT Earnings

Earnings (TTM)

16.9M

Earnings Growth (Yr)

106.99%

Earnings Growth (Qtr)

-20.89%

Breaking Down SRPT Revenue

Last 7 days

-3.2%

Last 30 days

-10.5%

Last 90 days

-6.8%

Trailing 12 Months

-9.9%

How does SRPT drawdown profile look like?

SRPT Financial Health

Current Ratio

4.05

Debt/Equity

0

Debt/Cashflow

-368.05

SRPT Investor Care

Shares Dilution (1Y)

1.48%

Diluted EPS (TTM)

0.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20241.4B000
2023975.7M1.0B1.1B1.2B
2022765.8M835.2M876.0M933.0M
2021573.4M600.1M645.6M701.9M
2020407.5M450.2M495.1M540.1M
2019323.4M344.6M365.1M380.8M
2018202.8M241.4M273.9M301.0M
201737.9M70.3M102.7M154.6M
20165.0M5.2M5.3M5.4M
20150004.9M
201415.8M15.5M12.4M9.8M
201330.6M22.3M18.9M14.2M
201243.9M43.5M43.6M37.3M
201142.5M50.1M48.9M47.0M
2010021.5M25.5M29.4M
200900017.6M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Sarepta Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 02, 2024
murray dallan
sold
-508,900
140
-3,635
chief customer officer
Mar 11, 2024
boor kathryn jean
sold
-93,549
122
-761
-
Mar 08, 2024
wigzell hans lennart rudolf
sold
-1,848,800
123
-15,000
-
Mar 08, 2024
arif bilal
sold (taxes)
-58,122
123
-472
chief tech ops officer
Mar 08, 2024
brown ryan edward
sold (taxes)
-110,703
123
-899
evp, general counsel
Mar 08, 2024
wigzell hans lennart rudolf
acquired
208,500
13.9
15,000
-
Mar 08, 2024
rodino-klapac louise
sold (taxes)
-111,934
123
-909
head of r&d, cso
Mar 08, 2024
estepan ian michael
sold (taxes)
-127,450
123
-1,035
chief financial officer
Mar 07, 2024
arif bilal
sold (taxes)
-60,967
120
-506
chief tech ops officer
Mar 07, 2024
brown ryan edward
sold (taxes)
-60,967
120
-506
evp, general counsel

1–10 of 50

Which funds bought or sold SRPT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 13, 2024
MOSAIC FAMILY WEALTH PARTNERS, LLC
unchanged
-
98,066
384,367
0.06%
Jun 11, 2024
EverSource Wealth Advisors, LLC
unchanged
-
755
3,166
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
987,000
3,998,000
0.01%
May 29, 2024
Garde Capital, Inc.
new
-
140,000
140,000
0.01%
May 24, 2024
Cetera Investment Advisers
added
27.55
645,817
1,552,360
-%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
added
102
200,943,000
317,630,000
1.44%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.56
1,289,900
2,333,900
0.30%
May 21, 2024
LRI Investments, LLC
new
-
4,919
4,919
-%
May 17, 2024
Ikarian Capital, LLC
added
14.81
6,923,440
19,713,900
2.16%
May 17, 2024
New Covenant Trust Company, N.A.
new
-
32,236
32,236
0.03%

1–10 of 33

Are Funds Buying or Selling SRPT?

Are funds buying SRPT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SRPT
No. of Funds

Unveiling Sarepta Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 07, 2024
blackrock inc.
10.7%
10,124,431
SC 13G/A
Feb 13, 2024
janus henderson group plc
5.7%
5,345,785
SC 13G/A
Feb 13, 2024
vanguard group inc
9.42%
8,816,124
SC 13G/A
Feb 09, 2024
capital international investors
5.1%
4,741,485
SC 13G
Jan 26, 2024
blackrock inc.
6.7%
6,266,973
SC 13G/A
Feb 14, 2023
sands capital management, llc
2.5%
2,151,378
SC 13G/A
Feb 10, 2023
janus henderson group plc
6.9%
6,028,016
SC 13G/A
Feb 09, 2023
vanguard group inc
9.15%
8,033,264
SC 13G/A
Feb 01, 2023
blackrock inc.
6.3%
5,557,234
SC 13G/A
Feb 14, 2022
sands capital management, llc
6.16%
5,364,627
SC 13G

Recent SEC filings of Sarepta Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 07, 2024
8-K
Current Report
Jun 07, 2024
SC 13G/A
Major Ownership Report
May 06, 2024
3
Insider Trading
May 06, 2024
4
Insider Trading
May 01, 2024
10-Q
Quarterly Report
Apr 24, 2024
ARS
ARS
Apr 24, 2024
DEF 14A
DEF 14A
Apr 24, 2024
DEFA14A
DEFA14A
Mar 28, 2024
S-8 POS
Employee Benefits Plan
Mar 28, 2024
S-8 POS
Employee Benefits Plan

Peers (Alternatives to Sarepta Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
0.28% 3.53%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.5B
2.0B
2.99% -23.67%
-58.61
9.71
75.20% 68.82%
16.0B
2.5B
8.50% -12.61%
77.77
6.46
13.74% 186.89%
13.8B
3.8B
7.60% -2.83%
18.51
3.66
8.58% 129.81%
MID-CAP
5.2B
107.9M
-8.24% 83.94%
-9.45
48.09
54.84% -28.31%
4.9B
524.1M
-2.95% -55.09%
-11.65
9.28
394.93% 39.61%
3.6B
251.0M
-0.68% -10.56%
-12.18
14.38
73.58% -86.73%
2.9B
240.7M
-4.80% -33.39%
-6.19
12.77
-1.03% -213.92%
2.5B
813.8M
0.54% -38.22%
-1.4K
3.02
56.43% 98.83%
1.9B
996.6M
5.92% 71.39%
-4.85
1.94
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.22% 22.70%
27.15
4.3
60.38% -34.49%
468.2M
881.7K
-2.64% 488.84%
-13.87
481.06
-77.61% 33.36%
221.8M
4.2M
-28.67% 45.58%
-1.78
53.32
-66.30% 48.24%
19.9M
2.1M
16.67% 230.00%
-0.86
7.61
-13.45% 69.54%

Sarepta Therapeutics Inc News

Latest updates
Defense World9 hours ago

Sarepta Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue4.2%413,464,000396,781,000331,817,000261,238,000253,500,000258,427,000230,269,000233,487,000210,830,000201,461,000189,406,000164,089,000146,931,000145,138,000143,924,000137,363,000113,674,000100,113,00099,041,00094,668,00087,011,000
Costs and Expenses1.7%378,559,000372,156,000352,659,000394,757,000391,588,000365,260,000361,624,000444,619,000297,711,000307,274,000223,864,000331,663,000298,796,000315,854,000280,992,000275,716,000231,700,000330,332,000222,631,000370,035,000163,398,000
  S&GA Expenses-3.6%127,003,000131,700,000120,893,000118,564,000110,714,000120,478,000104,787,000154,316,00071,840,00078,055,00061,127,00072,347,00071,131,00086,046,00075,373,00073,688,00082,768,00081,424,00075,429,00067,393,00060,566,000
  R&D Expenses--------------------113,266,00090,553,000
EBITDA Margin117.7%0.07-0.37-0.54-0.81-1.04-0.65-0.70-0.48-0.34-0.46-0.61-0.93---------
Interest Expenses805.3%7,188,000794,0007,312,000794,0007,023,0003,145,00013,493,00016,092,00011,688,00016,222,00011,947,00016,092,00011,688,00013,956,0005,430,0009,647,0005,385,0004,275,000---
Income Taxes200.7%5,300,000-5,261,5007,763,0009,355,0004,000,0007,938,0001,320,0003,388,000879,00092,000237,000-354,000-143,000832,00096,00020,000115,000711,000226,000174,00084,000
Earnings Before Taxes2.7%41,448,00040,371,000-33,174,000-14,585,000-512,710,000-101,306,000-256,418,000-228,093,000-104,146,000-121,889,000-47,907,000-81,759,000-167,393,000-188,485,000-196,403,000-150,800,000-17,377,000-234,992,000-126,100,000-276,229,000-76,559,000
EBT Margin105.8%0.02-0.42-0.60-0.88-1.13-0.74-0.81-0.60-0.46-0.60-0.75-1.06---------
Net Income-20.9%36,119,00045,655,000-40,937,000-23,940,000-516,755,000-109,244,000-257,738,000-231,481,000-105,025,000-121,981,000-48,144,000-81,405,000-167,250,000-189,317,000-196,499,000-150,820,000-17,492,000-235,703,000-126,326,000-276,403,000-76,643,000
Net Income Margin102.8%0.01-0.43-0.63-0.90-1.14-0.75-0.82-0.61-0.47-0.60-0.75-1.06---------
Free Cashflow-272.5%-274,520,000-73,696,000-144,379,000-140,143,000-218,881,000-100,356,000-73,195,000-75,893,000-106,726,000-31,532,000-133,570,000-115,040,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-1.2%3,2243,2653,1103,1263,0603,1283,1562,9973,0563,1482,6622,7592,7652,9852,7812,8832,9471,8231,7021,7481,964
  Current Assets-4.4%2,4652,5792,4512,4732,4882,5582,6262,4692,5312,6042,1852,2652,2712,4852,3232,4592,5471,4691,3621,4271,671
    Cash Equivalents-0.3%4274285428528729671,0398691,2342,1161,5991,6971,4821,5031,4751,6401,764835725809732
  Inventory15.7%374323244227203204221208199186288269240232220180173171166157140
  Net PPE9.8%249227212189183180181183187191199203203190172153137130120117106
Liabilities-5.9%2,2632,4052,3452,3842,3472,7432,7252,2702,1992,2202,1932,2742,2302,2231,8891,8401,8031,005707649615
  Current Liabilities-6.9%609654451499537620603546455453373425365416378355306265216162137
    LT Debt, Current0.1%106105-------------------
Shareholder's Equity11.9%9618597647417133854317268579284704855357628921,0431,1458189951,0991,349
  Retained Earnings0.8%-4,410-4,446-4,491-4,450-4,426-3,910-3,800-3,543-3,311-3,206-3,084-3,036-2,955-2,848-2,658-2,462-2,311-2,294-2,058-1,931-1,655
  Additional Paid-In Capital1.3%5,3725,3055,2575,1935,1404,2974,2354,2724,1694,1353,5543,5223,4913,6103,5513,5053,4563,1123,0533,0313,004
Accumulated Depreciation-------------------45.0038.0033.00
Shares Outstanding0.8%94.0094.0094.0093.0088.0088.0088.0087.0087.0081.0080.0080.00---------
Float----10,681,686---6,561,646---6,206---12,576---11,294-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-342.9%-242-54.66-114-122-209-92.39-64.96-66.81-101-29.33-124-109-180-174-238-107628-163-67.43-79.00-146
  Share Based Compensation-11.2%41.0046.0048.0047.0041.0051.0050.0010329.0030.0027.0029.0029.0030.0027.0028.0024.0022.0021.0020.0016.00
Cashflow From Investing440.0%219-64.36-21097.0012.0010.0019.00-289-785-2.5820.00321157-12354.00-34.22-17.6817.00-17.96152135
Cashflow From Financing1039.5%22.002.0015.006.0010211.002160.005.005496.004.003.0032719.0018.003192572.006.00378
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

SRPT Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Products, net$ 359,484$ 231,495
Type of Revenue [Extensible List]us-gaap:ProductMemberus-gaap:ProductMember
Collaboration and other$ 53,980$ 22,005
Total revenues413,464253,500
Cost and expenses:  
Cost of sales (excluding amortization of in-licensed rights)50,55935,017
Research and development200,396245,679
Selling, general and administrative127,003110,714
Amortization of in-licensed rights601178
Total cost and expenses378,559391,588
Operating income (loss)34,905(138,088)
Other income (loss), net:  
Loss on debt extinguishment0(387,329)
Other income, net6,54312,707
Total other income (loss), net6,543(374,622)
Income (loss) before income tax expense41,448(512,710)
Provision for Income tax5,3294,045
Net income (loss)36,119(516,755)
Other comprehensive income (loss):  
Unrealized gains (losses) on investments, net of tax(1,609)1,245
Total other comprehensive (loss) income(1,609)1,245
Comprehensive income (loss)$ 34,510$ (515,510)
Earnings (loss) per share:  
Earnings (loss) per common share, basic$ 0.38$ (5.86)
Earnings (loss) per common share, diluted$ 0.37$ (5.86)
Weighted average number of shares of common stock used in computing earnings (loss) per share  
Basic93,991,00088,186,000
Diluted99,114,00088,186,000

SRPT Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 427,290$ 428,430
Short-term investments963,4531,247,820
Accounts receivable, net378,806400,327
Inventory373,530322,859
Manufacturing-related deposits and prepaids238,821102,181
Other current assets82,96577,714
Total current assets2,464,8652,579,331
Property and equipment, net249,302227,154
Right of use assets126,269129,952
Non-current inventory207,542191,368
Other non-current assets176,407136,771
Total assets3,224,3853,264,576
Current liabilities:  
Accounts payable91,536164,918
Accrued expenses283,317314,997
Deferred revenue, current portion112,00050,416
Current portion of long-term debt105,586105,483
Other current liabilities16,27017,845
Total current liabilities608,709653,659
Long-term debt1,133,6601,132,515
Lease liabilities, net of current portion140,102140,965
Deferred revenue, net of current portion325,000437,000
Contingent consideration48,20038,100
Other non-current liabilities7,5223,000
Total liabilities2,263,1932,405,239
Commitments and contingencies (Note 14)
Stockholders’ equity:  
Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and outstanding00
Common stock, $0.0001 par value, 198,000,000 shares authorized; 94,490,157 and 93,731,831 issued and outstanding at March 31, 2024, and December 31, 2023, respectively99
Additional paid-in capital5,371,9685,304,623
Accumulated other comprehensive (loss) income, net of tax(691)918
Accumulated deficit(4,410,094)(4,446,213)
Total stockholders’ equity961,192859,337
Total liabilities and stockholders’ equity$ 3,224,385$ 3,264,576
SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEsarepta.com
 INDUSTRYBiotechnology
 EMPLOYEES1162

Sarepta Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Sarepta Therapeutics Inc? What does SRPT stand for in stocks?

SRPT is the stock ticker symbol of Sarepta Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sarepta Therapeutics Inc (SRPT)?

As of Tue Jun 18 2024, market cap of Sarepta Therapeutics Inc is 11.11 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SRPT stock?

You can check SRPT's fair value in chart for subscribers.

What is the fair value of SRPT stock?

You can check SRPT's fair value in chart for subscribers. The fair value of Sarepta Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sarepta Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SRPT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sarepta Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SRPT is over valued or under valued. Whether Sarepta Therapeutics Inc is cheap or expensive depends on the assumptions which impact Sarepta Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SRPT.

What is Sarepta Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jun 18 2024, SRPT's PE ratio (Price to Earnings) is 657.42 and Price to Sales (PS) ratio is 7.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SRPT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Sarepta Therapeutics Inc's stock?

In the past 10 years, Sarepta Therapeutics Inc has provided 0.139 (multiply by 100 for percentage) rate of return.